Cite

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

MLA

Ucl - Sss, IREC/MIRO-Pôle d’imagerie moléculaire, radiothérapie et oncologie, et al. “Pembrolizumab Alone or Combined with Chemotherapy versus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-Label, Phase 3 Trial.” The Lancet. Oncology, Vol. 22, No.7, p. 931-945 (2021), 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1328223815&authtype=sso&custid=ns315887.



APA

Ucl - Sss, I.-P. d’imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d’oncologie médicale, Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., Fléchon, A., Gunduz, S., Loriot, Y., Rodriguez-Vida, A., Mamtani, R., Yu, E. Y., … Machiels, J.-P. (2021). Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. The Lancet. Oncology, Vol. 22, No.7, p. 931-945 (2021).



Chicago

Ucl - Sss, IREC/MIRO - Pôle d’imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d’oncologie médicale, Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, et al. 2021. “Pembrolizumab Alone or Combined with Chemotherapy versus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-Label, Phase 3 Trial.” The Lancet. Oncology, Vol. 22, No.7, p. 931-945 (2021). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1328223815&authtype=sso&custid=ns315887.